Systems biology of cisplatin resistance: past, present and future
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyMolecular mechanisms of cisplatin resistance in cervical cancerMitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer ChemotherapyChloroquine and hydroxychloroquine for cancer therapyTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyTargeting Hsp90 in urothelial carcinomaDrugging the addict: non-oncogene addiction as a target for cancer therapyTCRP1 contributes to cisplatin resistance by preventing Pol β degradation in lung cancer cellsMultidrug Resistance-Associated Protein 2 Expression Is Upregulated by Adenosine 5'-Triphosphate in Colorectal Cancer Cells and Enhances Their Survival to Chemotherapeutic DrugsCisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian TumorsUse of Accelerator Mass Spectrometry in Human Health and Molecular ToxicologyRegulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells.Synergistic effects of a novel lipid-soluble extract from Pinellia pedatisecta Schott and cisplatin on human cervical carcinoma cell lines through the regulation of DNA damage response signaling pathwayDNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer.USP22 Induces Cisplatin Resistance in Lung Adenocarcinoma by Regulating γH2AX-Mediated DNA Damage Repair and Ku70/Bax-Mediated ApoptosisAutophagy inhibition impairs the epithelial-mesenchymal transition and enhances cisplatin sensitivity in nasopharyngeal carcinoma.p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway.Vitamin B6 improves the immunogenicity of cisplatin-induced cell death.Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cellsSmall-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.Spontaneous Transformation of Murine Oviductal Epithelial Cells: A Model System to Investigate the Onset of Fallopian-Derived Tumors.Micheliolide overcomes KLF4-mediated cisplatin resistance in breast cancer cells by downregulating glutathioneSynergistic effect of allyl isothiocyanate (AITC) on cisplatin efficacy in vitro and in vivo.Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian CancerWEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistanceIKK phosphorylation of NF-κB at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancerAutophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway.Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivityA Comprehensive Review on the Genetic Regulation of Cisplatin-induced NephrotoxicityLow-dose cisplatin-induced CXCR4 expression promotes proliferation of ovarian cancer stem-like cells.Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer.PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.Resveratrol and STAT inhibitor enhance autophagy in ovarian cancer cells.Trial Watch: Immunotherapy plus radiation therapy for oncological indications.Aquaporin 3 facilitates chemoresistance in gastric cancer cells to cisplatin via autophagy.The P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non-Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy.Elevated HOTAIR expression associated with cisplatin resistance in non-small cell lung cancer patients
P2860
Q26745686-D291209B-3A76-446C-8316-22583A45499AQ26746228-C102BD82-9F29-430F-BCA3-58A40348BF70Q26797353-C68748A8-F771-468B-9BB6-1224FDFF2A67Q26827797-319E0381-CD1D-4865-9EC1-20C292108F4FQ27004011-49CDA75E-EC60-46A7-8B95-A3BD8DB39023Q27023406-E9804A45-DFD6-469E-AC28-D8BCB7B1C987Q28079559-D692B454-58C9-4118-8CAD-EA3B34862126Q28118898-109F11C2-F994-40CA-B99F-611E831DD8B4Q28547426-2D18D886-EF2C-46C7-80B5-C58954F4192FQ28550863-FE2175CA-E71B-406B-8DDE-02520BE1A4C6Q28818313-5D56A55D-DEC8-40EA-8836-12901D5A130BQ33597807-35A1CF79-2ED1-4D10-8657-A584789CA68EQ33597926-7701358A-DB47-400F-A4C9-718F400F8CFAQ33685402-721BA469-1927-4BE0-90F8-86E06267B2E4Q33696463-44515D77-B94B-41AB-A450-4DE3ADE40EC7Q33751245-AB932626-41DD-478E-B4DF-AD45276951BCQ33873642-D867CA69-F93B-4AC9-8893-5B58812BAD5FQ34742904-8F9930A1-EE21-4D63-8704-EF79F17458C3Q34933129-D9024842-44B0-4D58-8758-269A6F5BF037Q35538822-55D59675-1094-4804-A471-2B5211959EFDQ35743521-758FA212-BD27-417A-9487-EB763239ADD6Q35859678-3D51A40A-192E-41C6-98CD-3363DB7A9C88Q36024718-9565F1E7-A59B-4883-9262-166E2C4F20DDQ36057163-2A8F3570-626C-4386-85A3-30E3B945104CQ36167088-AD1CE472-D17A-4B69-A104-C90D26F9E0FAQ36297939-0564165F-B03E-4453-8C8A-5917D2896697Q36309403-A526556B-D39B-41A9-B340-25E5415C7764Q36390671-062D6BC1-CF22-45E4-9827-D25E3C13FF6CQ36433289-FAB8022A-1374-431C-8A66-857A4C33BDC8Q36545734-273D7988-D385-4D4E-B83D-6BDE8B2048E7Q36634788-5C588216-C329-4DB6-863D-75C84FE0DB70Q36906569-FF5B9709-2672-4AC1-881F-27D07BB8BE4DQ36947111-79D1D703-3E51-4CF5-A9B1-B0B7FE9E1276Q37142438-8B8ED4B6-9B62-4E79-9D6E-CCB6909F07D2Q37153875-1275F325-B6E1-4A04-8B8B-1219F3D56531Q37164378-51450B47-F2DC-4E4E-8175-F84386A4F8FEQ37308207-7A130F6D-D28C-4DE0-87ED-315C645E6172Q37412002-DC650173-E012-450A-B1B1-B4416BC6D446Q37414070-840B5EEA-E48E-4D27-A45B-DBCEF605F95AQ37528206-3F836CD8-E819-4EEB-8C96-6C1F15432E8E
P2860
Systems biology of cisplatin resistance: past, present and future
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Systems biology of cisplatin resistance: past, present and future
@ast
Systems biology of cisplatin resistance: past, present and future
@en
Systems biology of cisplatin resistance: past, present and future
@nl
type
label
Systems biology of cisplatin resistance: past, present and future
@ast
Systems biology of cisplatin resistance: past, present and future
@en
Systems biology of cisplatin resistance: past, present and future
@nl
prefLabel
Systems biology of cisplatin resistance: past, present and future
@ast
Systems biology of cisplatin resistance: past, present and future
@en
Systems biology of cisplatin resistance: past, present and future
@nl
P2093
P2860
P50
P921
P3181
P356
P1476
Systems biology of cisplatin resistance: past, present and future
@en
P2093
P2860
P3181
P356
10.1038/CDDIS.2013.428
P407
P5008
P577
2014-05-29T00:00:00Z